The GATA transcription factors consist of six family members, which bind to the consensus DNA-binding element, W-GATA-R, and are poorly characterized in the central nervous system (CNS). Using retroviral gene trapping on transgenic mouse glioma models, we identified GATA6 to be a novel tumor suppressor gene in glioblastoma multiforme. We now show GATA4, a family member of GATA6, to be expressed in the neurons and glia of normal murine and human embryonic and adult CNS. Silencing GATA4 in normal astrocytes did not alter their growth properties. In contrast, knockdown of Gata4 in p53 null non-transformed murine astrocytes induced transformation, with increased proliferation and resistance to chemotherapy or radiation-induced apoptosis. Furthermore, GATA4 expression was lost in a panel of human malignant astrocytoma cell lines. GATA4 overexpression in normal human and murine astrocytes resulted in a cell cycle block in G1 phase, with increased apoptosis. Mechanistically, GATA4 was a transcriptional inducer of the cyclin-dependent kinase inhibitor, p15INK4B, leading to the attenuation of cyclin D1. GATA4 expression was also induced by transforming growth factor-b, leading to the inhibition of astrocyte proliferation. Collectively, we show that GATA4 is expressed in the embryonic and adult CNS and acts as a negative regulator of astrocyte proliferation and growth.
Introduction
The GATA family of transcription factors consists of six members that have two highly conserved zinc-finger domains and recognize a consensus DNA-binding motif of (A/T)/GATA/(A/G) (Lowry and Atchley, 2000) . They regulate biological functions, including organogenesis, differentiation, proliferation and apoptosis (Perlman et al., 1998; Koutsourakis et al., 1999; Lowry and Atchley, 2000; Cantor and Orkin, 2002; Wada et al., 2002) . GATA-1, -2 and -3 are important for the development of the nervous system and hematopoietic cell lineages (Cantor and Orkin, 2002; Patient and McGhee, 2002) . In contrast, GATA-4, -5 and -6 are implicated in organogenesis, specifically the development of the heart, ovary and extraembryonic tissues. Gata4 and Gata6 knock-out mice are embryonic lethal at E8.5-9.5 and E6.5-7.5, respectively, whereas Gata5 knock-out mice are viable. The embryonic lethality arises because of the defects in cardiogenesis and visceral endoderm formation, respectively (Kuo et al., 1997; Morrisey et al., 1998) . Although originally thought to be selectively expressed in the heart and gastrointestinal tract, from these knock-out mouse data, the GATA-4-5-6 subfamily is now being identified in several other organ systems and disease states, including the central nervous system (CNS), where it is poorly characterized. GATA4 has been implicated in regulating the differentiation of gonadotropin releasing hormone neurons , and our study showed GATA6 expression in the neurons and glia in both the embryonic and adult CNS (Kamnasaran and Guha, 2005) . Using a gene-trap mutagenesis strategy on a spontaneous transgenic murine glioma model developed in our laboratory, we identified GATA6 as a novel tumor suppressor gene. Loss of GATA6 was involved in glioma progression not only in the murine model, but also in the human glioblastoma (glioblastoma multiforme (GBM)), the most common and malignant primary CNS tumor (Kamnasaran et al., 2007) . These observations on GATA6 furthered our interest in other GATA members in the CNS, particularly GATA4, since both GATA6 and GATA4 are embryonic lethal and have similar tissue expression patterns in the CNS.
The expression and function of GATA4 in the CNS is not well defined and is the subject of our current study on murine and human systems. We show ubiquitous CNS expression of GATA4 in various cellular compartments at varying developmental time points in both neurons and glia. Astrocyte, the most abundant glia, is the focus of our attention. Using primary murine astrocyte cultures and a non-transformed immortalized human astrocyte cell line, we show that GATA4 is sufficient to suppress cell proliferation and induce apoptosis.
Interestingly, we show that loss of Gata4 in nontransformed but genetically susceptible murine astrocytes harboring p53 loss synergistically increases their proliferation potential and resistance to apoptosis. We further this finding by showing that Gata4 silencing in cooperation with p53 loss induces in vitro transformation. Transforming growth factor-b (TGF-b), a potent inducer of p15INK4B, increases GATA4 expression, a potential mechanism by which TGF-b exerts its antiproliferative effects on human and murine astrocytes. Collectively, our findings show both the ubiquitous expression of GATA4 in the human and murine CNS and its functional role in several key cellular processes, such as, negative regulation of proliferation and positive regulation of apoptosis.
Results
GATA4 is expressed ubiquitously in post-natal and adult human CNS Our interest in GATA4 commenced with the result that a panel of six well-characterized human GBM cell lines had complete loss GATA4, similar to our prior report on GATA6 (Kamnasaran et al., 2007) , compared with a non-transformed but immortalized normal human astrocyte (NHA) cell line (Sonoda et al., 2001) (Figure 1a) . However, compared with GATA6 expression in the CNS, which we had previously characterized (Kamnasaran and Guha, 2005) , the CNS characterization of GATA4 at the cellular and developmental level was lacking. To generate a comprehensive in vivo human paraffin-embedded human brain samples and developmental tissue microarrays that contained tissue sections of varying anatomical sections and tissue of post-natal and adult CNS. GATA4 expression was ubiquitous in 6-month-old post-natal human and adult brain with GATA4 expression semi-quantified in several anatomical compartments and varying cell types: such as neurons, Bergmann Glia, oligodendrocytes and endothelial cells (Table 1 ). GATA4 nuclear staining was observed in adult cortex, including neurons (Figure 1b , I-iii), oligodendrocytes (Figure 1b, and endothelial cells (Figure 1b, vi) . Astrocytes, the most abundant glial cell in the human CNS, were then assessed for GATA4 expression. GATA4 nuclear staining was observed at the protein level by immunofluorescence (IF) in our NHA cell line with GFAP used as an astrocyte-specific marker (Figure 1c, . GATA4 transcript was also detected in the human brain cDNA and astrocyte cDNA by reverse transcriptase-PCR (Supplementary Figure 1a) . U87 cells, an astrocytoma cell line devoid of GATA4 and GFAP was used as a negative control for IF analysis (Supplementary Figure 1c) .
Gata4 is expressed ubiquitously in the embryonic and adult murine CNS Mouse Gata4 and human GATA4 is 96% homologous at the protein level. To complement our post-natal and adult human CNS observations, we investigated the embryonic and adult murine brains for Gata4 expression. Immunohistochemical analysis showed Gata4 to be ubiquitously expressed in murine embryo (E16.5) CNS in several cell types, including choroid plexus epithelial cells (Figure 2a, i) , ependymal cells (Figure 2a , ii) and cells in the germinal matrix, which are highly abundant for progenitor cells that give rise to neurons and astrocytes (Temple, 2001) (Figure 2a , iii). Gata4 expression was observed in neurons (Figure 2a, v) but was absent in outer compared with inner cortical layers of murine embryos (Figure 2a, iv) . A similar Gata4 ubiquitous profile was observed in 1-month-old adult mice where Gata4 expression was observed in the nuclei of the neurons (TUJ1-positive) in the dentate gyrus (Figure 2b, vi) and in the frontal cortex (Figure 2b, vii) . Endothelial cells (Figure 2b, viii) were also Gata4-positive. This pattern was also observed in 3-month-old adult mice (data not shown). Similar to our human data, the most abundant glial cell, astrocytes, were then assessed for Gata4 expression. Gata4 transcript was detected in murine astrocytes (Supplementary Figure  1b) , with IF analysis showing Gata4 staining positively in the nuclei of primary murine adult astrocytes (Figure 2c , i-iv) marked with GFAP. Collectively, our human and murine data show ubiquitous Gata4 Functional analysis of GATA4 in cell cycle control of human and murine astrocytes We focused our functional analysis of GATA4 to astrocytes, as our prior study implicates GATA6 to be a tumor suppressor in human GBMs (Kamnasaran and Guha, 2005; Kamnasaran et al., 2007) and our current findings show GATA4 expression to be lost in a majority of human GBM cell lines, Figure 1a . We used loss and gain of function studies of GATA4 using GATA4 small interfering RNA (siRNA)-mediated gene silencing and overexpressing GATA4 using the fulllength human and murine GATA4 cDNA. GATA4 knockdown by two separate siRNA in NHA (Figure 3a) did not alter the cell cycle significantly compared with controls ( Figure 3c ). GATA4 siRNA did not alter GATA6 protein levels after 48 h of treatment, indicating that the siRNA was specific to GATA4 and not to its close family member, GATA6, in both human and mouse (Supplementary Figure 1d) . In contrast, overexpressing human GATA4 in NHA (Figure 3a) increased the number of NHA in the subG1 and G1 phase significantly, P ¼ 0.02 (Figure 3b and c). The significant increase of cells in the G1 phase suggested either G1 arrest or decreased proliferation, thus we analysed the cells with a panel of cell cycle markers. We observed induction of the inhibitor of cyclin, p15INK4B, and downregulation of cyclin D1 and cyclin D2 (Figure 3d ). There was no change in other cell cycle inhibitors such as p14ARF or p16INK4A (Figure 3d ). Similar to NHAs, two separate Gata4 siRNAmediated gene silencing in normal murine astrocytes (NMAs) (Figure 3e ) did not result in any cell cycle changes compared to controls (Figure 3f ). Overexpression of Gata4 increased the cell population in the G1 phase and subG1 phase of the cell cycle, P ¼ 0.02 (Figure 3f and g ), similar to our results on NHA. Further, characterization of cell cycle proteins showed that p15Ink4b was specifically induced at the G1 stage arrest phase, with downregulation of cyclin D1 compared with controls ( Figure 3h ), with no changes in p19Arf and p16Ink4a.
GATA4 overexpression, but not silencing, alters human and murine astrocyte proliferation GATA4 knockdown in NHA or NMA did not alter cell cycle or cell proliferation measured by thymidine incorporation over a 5-day period (Figure 4a and b) . In addition, no significant changes in cell viability using MTS viability assay as an indirect measure of proliferation was observed in NHA or NMA ( Supplementary  Figure 2a and b) . In contrast to knockdown, overexpression of GATA4 in both NHA and NMA led to alterations in the cell cycle with induction of p15INK4B. Human and murine astrocyte were transiently transfected with their respective species-specific cDNA plasmid constructs. Thymidine incorporation assay over a 5-day period after transfection showed decreased proliferation of both NHA and NMA, compared with empty vector controls, which was statistically significant at days 2 and 3 (after transfection), P ¼ 0.01 (Figure 4c and d). Significance was lost on day 5 as levels of GATA4 were returning to normal compared with days 2 and 3 where expression was the highest (Figure 4c and 4d, see bottom panel for densitometry ratios).
GATA4 regulation of human and murine apoptosis GATA4 overexpression showed a significant increase of NHAs in the subG1 phase of the cell cycle (P ¼ 0.003) compared with controls, suggestive of increased apoptosis (Figure 3a and b). Caspase 3/7 activity, a marker of active apoptosis, was significantly increased (P ¼ 0.01) with GATA4 overexpression in NHAs Figure 5a . Loss of GATA4 conferred no change to activated Caspase 3/7 levels compared with controls. In addition, NHAs overexpressing GATA4 subjected to chemotherapy (camptothecin) and radiation (5 Gy), commonly used treatment modalities in GBMs, also had a significant GATA4, a regulator of astrocyte cell proliferation and apoptosis S Agnihotri et al increase (Po0.01) in activated Caspase 3/7, Figure 5a . Further support of GATA4-mediated increased apoptosis in NHAs was shown by significant (Po0.001) induction of pro-apoptotic genes, such as BAX and APAF-1 compared with empty vector controls at the RNA level, Figure 5b . No changes of the BCL-2 gene, a previously reported GATA4-regulated gene, were seen in NHAs (Kobayashi et al., 2006) . Annexin-V-phycoerythrin (PE) staining, a direct measure of apoptosis was undertaken on NHAs and NHAs overexpressing GATA4 both under camptothecin treatment. NHAs overexpressing GATA4 had a significant population of cells in the early/late apoptotic phase (M2 peak) versus NHAs transfected with empty vector controls Figure 5c (92 versus 34%, Po0.001). NHAs overexpressing GATA4 also had a significantly lower level of viable cells (M1 peak) compared with empty vector controls, Figure 5c (8 versus 64%, Po0.001). The observations on apoptosis in NHAs were similar to primary NMAs. Overexpression of Gata4, but not Gata4 knockdown, induced a significant increase in activated levels of Caspase 3/7 in both a non-apoptotic and apoptoticinducing (camptothecin, 5-Gy radiation) environment, Po0.01, Figure 5d .
Loss of Gata4 in p53 À/À murine astrocytes synergistically increases proliferation and apoptosis resistance Knockdown of GATA4 in non-transformed genetically stable NHAs and NMAs did not result in a significant change in proliferation or apoptosis compared with controls ( Figures 3, 4 and 5). We next queried the effect of altering Gata4 in more genetically unstable astrocytes, such as low-passage non-transformed p53À/À (null) murine astrocytes, which exhibit increased proliferation and resistance to apoptosis compared with NMAs (Bogler et al., 1999; Rempe et al., 2007) . In this genetic context, Gata4 knockdown by siRNA synergistically increased proliferation of p53 null astrocytes compared with controls, with statistical significance (Po0.002) at days 2-5, Figure 6a . Cell viability of p53 null murine astrocytes with knockdown of Gata4 also increased compared with controls ( Supplementary  Figure 2c) . In contrast, Gata4 overexpression in p53 null astrocytes decreased their proliferation over a 5-day One-month-old adult murine brain. Gata4 stained positively in neurons (N) of the dentate gyrus (vi) and neurons of the cortex (vii). Tuj1 was used as a neuronalspecific marker. Gata4-positive staining was also seen in endothelial cells (EC) (vii). (c) Immunofluorescence of Gata4 in primary murine astrocytes. Gata4 stained positive in the nucleus of primary murine astrocytes (ii), with GFAP used as an astrocyte-specific marker (iii). DAPI (i) was used as a nuclear stain. (iv) Merged image with all three fields. Scale bar of whole brain at lowmagnification panels represents 500 mm and scale bar at all other panels represents 50 mm.
GATA4, a regulator of astrocyte cell proliferation and apoptosis S Agnihotri et al period after transfection, which was significantly (Po0.05) different on days 2 and 3, Figure 6b . Significance was lost on day 5 as Gata4 levels retuned to normal (Figure 6b , bottom panel western blot). Transient overexpression of Gata4 also correlated with induction of p15Ink4b by day 5, but as Gata4 levels returned to endogenous levels, p15Ink4b levels also diminished. The strongest effect was seen on day 3 with attenuation of cyclin D1 and induction of p15Ink4b, Figure 6c . In addition to inhibiting proliferation, overexpression of Gata4 was able to induce activated Caspase 3/7 (Figure 6d , *Po0.05) in the p53 null astrocytes, which were sensitized to apoptosis when subjected to 5-Gy irradiation or camptothecin (Figure 6d , *Po0.05, Supplementary Figure 3e and f) . Interestingly, loss of Gata4 in these p53 null astrocytes significantly reduced the levels of activated Caspase 3/7 (Figure 6d, *Po0.05), with accompanying increased resistance to apoptosis when subjected to irradiation or camptothecin.
Combined loss of Gata4 and p53 induces in vitro transformation Loss of Gata4 in a p53 null background displayed properties of transformed cells, such as increased proliferation and resistance to apoptosis, Figure 6 . To assess the effect of long-term Gata4 silencing, we generated p53 null astrocytes with long-term Gata4 silencing using retroviral-mediated Gata4 short hairpin RNA (shRNA) transfer, Figure 7a . Combined loss of Gata4 and p53 was sufficient to induce anchorageindependent growth as a marker of in vitro transformation compared with non-Gata4-silenced p53 null astrocytes. p53 null astrocytes were unable to form colonies in soft agar (Figure 7c , i and ii) as were p53 null cells with shRNA control vector, Figure 7c , iii and iv. In contrast, p53 null astrocytes with Gata4 inhibited (shRNA1 or shRNA2) did form anchorage-independent colonies in soft agar, Figure 7c , v-viii. Figure 7b quantifies the colony-forming units generated by p53 null and GATA4 shRNA astrocytes compared with controls with significant colony-forming units induced with Gata4 shRNA (P ¼ 0.001). As seen in our transient Gata4 siRNA experiments, stably expressing Gata4 shRNA astrocytes have resistance to apoptosis when subjected to apoptotic stimuli such as camptothecin or 5-Gy irradiation, Figure 7d . Resistance to apoptosis was measured as reduced levels of activated Caspase 3/7. In addition to apoptotic resistance, Gata4 knockdown in p53 null astrocytes increased proliferation capacity of these astrocytes compared with controls on days 2, 3 and 5 (Po0.05). In summary, Gata4 loss in combination with p53 loss was sufficient to transform murine astrocytes and confer a proliferation advantage and apoptotic resistance.
TGF-b stimulates GATA4 expression in human and murine astrocytes Our results of the anti-proliferative effects of exogenous GATA4 overexpression led us to hypothesize that an endogenous system may be able to upregulate GATA4 levels. Induction of p15INK4B, a potent target of TGFb-mediated tumor suppression, along with our observation that GATA4 induced its proliferation block by p15INK4B, led us to hypothesize that GATA4 may be a target of TGF-b. GATA4 was induced by TGF-b stimulation from 8-24 h by approximately twofold and was reduced to normal levels by 48 and 72 h in human and murine astrocytes, Figure 8a . Increase in GATA4 protein expression correlated with p15INK4B induction of TGF-b stimulation, Figure 8a . TGF-b induced antiproliferation, with reduction of 5-bromodeoxyuridine incorporation most effective at 16-24 h, when the levels of GATA4 and p15INK4B were the highest (Supplementary Figure 3a and b) . SMAD3 translocation to the nucleus was used as a positive control to confirm effective TGF-b stimulation (Supplementary Figure 3c) . Therefore, exogenous GATA4 overexpression and endogenous GATA4 induction by TGF-b correlated with p15INK4B induction. We next sought to determine if GATA4 was essential for induction of p15INK4B and important in TGF-b-induced anti-proliferation. NHA cells and NHA cells treated with siRNA control had a significant (Po0.05) reduction of proliferation when stimulated with TGF-b compared with non-stimulated cells, Figure 8b Figure 3d) .
The p15INK4B locus contains a consensus GATA element at À788 bp in the human promoter and at À792 bp of the murine p15Ink4b promoter, Figure 8c . To address the issue if GATA4 is associated with the promoter of p15INK4B in human and mice, we carried out chromatin immunoprecipitation (ChIP) analysis. Under TGF-b-stimulated conditions or transient overexpression of GATA4, there was significant enrichment of GATA4 in the p15INK4B human and murine promoter, Figure 8d and data not shown. A distal partial GATA site was used as a negative control and was not enriched, Figure 8d .
Discussion
The subfamily of GATA transcription factors, GATA-4, -5 and -6, are poorly characterized in the human and murine CNS. We have established a compendium of GATA4 expression in the CNS of both humans and mice in varying cells and have highlighted several functional roles of GATA4 in astrocytes. Our study is the first to show specifically that GATA4 is expressed at varying developmental stages and within different cell types of the murine and human brain. Our finding that Gata4 is expressed in the germinal matrix of the E16.5 murine embryo was of great interest. The germinal GATA4, a regulator of astrocyte cell proliferation and apoptosis S Agnihotri et al GATA4, a regulator of astrocyte cell proliferation and apoptosis S Agnihotri et al matrix is a vascularized region of the developing brain that consists of a stem cell niche where progenitor cells migrate outwards and develop into neurons or glial cells (Temple, 2001 ). Gata4 expression was also observed in the dentate gyrus of adult mice, a key site of neurogenesis in the adult brains. The exact role of GATA4 in neuronal and glial cell development is still unanswered. To complement our expression profile, we investigated GATA4 function in murine and human astrocytes. We chose to investigate the role of GATA4 in normal non-transformed astrocytes as the role of GATA4 in these cells is not known and transformed cells may have GATA4 regulators, interactors and targets aberrantly expressed. In contrast to GATA4 silencing that did not confer any change in the cell cycle, overexpression of GATA4 increased the population of cells in the subG1 and G1 phase with the specific induction of the cyclin-dependent kinase inhibitor, p15INK4B, and attenuation of cyclin D1. This is the first study to implicate p15INK4B induction by a GATA family member. GATA transcription factors and their role in cell cycle is not fully understood but it has been shown that GATA6 can induce cell cycle arrest by induction of p21CIP1 in glomerular and vascular smooth muscle cells (Perlman et al., 1998; Setogawa et al., 2006) . GATA4 also sensitized astrocytes to apoptosis when subjected to apoptotic stimuli with increases in proapoptotic genes, such as Caspase 3/7, APAF-1 and BAX. Whether these genes are direct targets of GATA4 are of biological and therapeutic interest. In cardiomyocytes, GATA4 mediates a pro-survival effect by induction of the anti-apoptotic gene BCl-2 (Kobayashi et al., 2006) . We observed no change of BCL-2 in our GATA4-induced studies, although this might be attributed to differing microenvironments and varying GATA4-interacting transcriptional cofactor profiles between the CNS and the heart. We complemented our exogenous GATA4 overexpression results above with endogenous regulation of GATA4 and its growth effects on astrocytes. We focused on TGF-b as GATA4 induced p15Ink4b, known to be regulated by TGF-b, including in astrocytes (Hannon and Beach, 1994; Quelle et al., 1995) (Rich et al., 1999) . We found TGF-b stimulation induced GATA4 expression in astrocytes, a result which was also supported by studies in regulation of gastrointestinal differentiation genes (Afouda et al., 2005; Anttonen et al., 2006; Belaguli et al., 2007) . Furthermore, our results showed that GATA4 knockdown inhibited TGF-b and p15Ink4b-mediated growth suppression in the astrocytes. Collectively these results suggest that GATA4 induces p15INK4B in human and murine astrocytes through TGF-b signaling. In keeping with these findings, ChIP analysis showed GATA4 enrichment in the murine and human p15INK4B promoter region. The anti-proliferative effect of TGFb was also partially blocked with GATA4 siRNA as were p15INK4B levels, suggesting that the TGF-binduced anti-proliferation effect may be partially mediated through GATA4 in astrocytes. The SMAD 2/3/4 transcription factor complex is another potent activator of p15INK4B (Rich et al., 1999) and could explain why loss of GATA4 did not completely reduce p15INK4B levels and the anti-proliferative phenotype of TGF-b. Taken together, our observations suggest a model where GATA4 mediates its anti-proliferation effect through induction of p15INK4B and its proapoptotic effect through elevated levels of activated Caspase 3/7, Figure 8e .
In contrast to normal astrocytes, we showed that in p53 null astrocytes, which exhibit higher proliferation and resistance to apoptosis compared with normal astrocytes (Reilly et al., 2000; Rempe et al., 2007) , knockdown of Gata4 conferred a proliferation advantage to these cells. This suggests that GATA4 may work with p53 in concert to regulate cell cycle and proliferation, and loss of Gata4 removes another level of negative regulation in these cells. Indeed, the phenotypes observed from co-loss of GATA4 and p53, such as increased proliferation and resistance to apoptosis, were strong indicators that this combination may be sufficient to transform these astrocytes. Furthermore, stable knockdown of Gata4 induced transformation of p53 null astrocytes as they gained anchorageindependent growth in vitro. Although out of the scope of this study, whether GATA4 and p53 combined loss can initiate transformation in vivo would be a valuable question to answer and may shed light on the p53 tumor suppressor network.
Loss of GATA4 expression is observed in several cancers, such as squamous cell, ovarian and lung cancers (Capo-chichi et al., 2003; Guo et al., 2004 Guo et al., , 2006 Caslini et al., 2006) . In addition, GATA4 loss by deletion of chromosome 8p or mutation has been implicated as a predisposing factor in patients with congenital heart disease (Garg et al., 2003; Reamon-Buettner et al., 2007) . In our ongoing study in GBMs, the most malignant and devastating brain tumor, we observed a high loss of GATA4. We have also seen loss of GATA4 in other brain tumors such as low-grade gliomas and oligodendroglio- Overexpression of GATA4 in normal human astrocytes (NHAs) using CMV-GATA4 plasmid increases GATA4 levels after 48 h compared with empty vector control, and increases cells in the G1 and subG1 phase of cell cycle using flow cytometry, *Po0.05. (c) GATA4 knockdown has no effect on cell cycle compared with controls and GATA4 overexpression increases cell population in the subG1 and G1 phase, *P ¼ 0.02. (d) Western blot analysis of a panel of cell cycle proteins shows GATA4 overexpression induces p15INK4B, downregulates cyclin D1 and cyclin D2, but does not affect p16INK4A or p14ARF. (e) Gata4 siRNA treatment in murine astrocytes yields full knockdown of protein, bottom of western blot shows representative densitometry results. (f) Overexpression of murine Gata4 increases levels of Gata4 compared with empty vector controls, with subsequent increase of cells in the G1 and subG1 phase, *Po0.05. Cells were transfected with Gata4 plasmid and assessed for protein content after 48 h (g) Flow cytometry in murine astrocytes increases cells in subG1 and G1 phase of cell cycle, *Po0.02. (h) Cell cycle marker p15Ink4b was upregulated, whereas p19Arf was not. Cyclin D1 levels were also reduced as detected by western blot analysis. NMA, normal murine astrocyte.
GATA4, a regulator of astrocyte cell proliferation and apoptosis S Agnihotri et al mas (unpublished results). Having established GATA6 as a novel astrocytoma tumor suppressor and given the functions of GATA4 shown in this study, it is provoking to speculate that GATA4 may also serve as a tumor suppressor gene in astrocytomas.
Materials and methods

Immunohistochemistry and immunofluorescence
Sections of formalin-fixed paraffin-embedded specimens of the murine brain of 16.5-day-old embryos and 1-monthold adults were obtained from CD1 strain mice. Normal Figure 4 GATA4 overexpression and not knockdown effects proliferation. (a) Thymidine incorporation as a measure of proliferation was not significantly different in normal human astrocytes (NHAs) with GATA4 knockdown, a western blot showing a representative GATA4 knockdown over a 5-day period after small interfering RNA (siRNA) treatment.(b) Thymidine incorporation was also not statistically different in murine astrocytes with a representative western blot showing knockdown of Gata4 over a 5-day period after siRNA treatment, control represents untransfected astrocytes (c and d). GATA4 overexpression in human (c) and murine astrocytes (d) decreased thymidine incorporation on days 2 and 3, *Po0.01 after GATA4 transfection. Empty vector and NHAs with GATA4 expression vectors were compared with untransfected day 0 controls for fold difference values to generate the growth curve. Western blots showing status of GATA4 overexpression over a 5-day period after transfection with densitometry analysis underneath. Fold 5-bromodeoxyuridine (BrdU) increase for growth curves were normalized to day 0 transfected astrocyte luminescence values.
GATA4, a regulator of astrocyte cell proliferation and apoptosis S Agnihotri et al human brain was obtained from the IREB-approved Nervous System Tumor Bank at the University Health Network, Toronto. Tissue microarrays containing brain tissue from various anatomical regions from 6-month-old infant and adult humans were constructed as previously described (Ray et al., 2004) . Primary antibodies used are as follows: GATA4 monoclonal antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA, 1:100), TUJ1 monoclonal antibody (Chemicon International Inc., Billerica, MA, USA, 1:500) and NeuN antibody (Chemicon International Inc. 1:200).
Cell cultures
Non-transformed immortalized human astrocytes (NHA) (Sonoda et al., 2001) were grown in Dulbecco's modified Eagle's medium (Wisent ST-BRUNO, Quebec, Canada) and supplemented with 10% fetal bovine serum. NMA cultures were established from 1-month-old adult CD1 mice (Jackson Labs, Bar Harbor, ME, USA) as previously described (Luo et al., 2000; Kamnasaran et al., 2007) . p53 À/À murine astrocytes were a gift from Dr Tak W Mak (University of Toronto). Mice were maintained in accordance with the GATA4, a regulator of astrocyte cell proliferation and apoptosis S Agnihotri et al University Health Network hospital's animal protocols. The purity of murine astrocytes was more than 95%, as determined by IF assay with anti-glial fibrillary acidic protein antibody to identify astrocytes.
Stimulation assays
Briefly, cells were serum starved in Dulbecco's modified Eagle's medium (0% fetal bovine serum) for 16 h and stimulated with TGF-b1 at a concentration of 10ng/ml.
Transfection assays
For siRNA-mediated gene silencing, human astrocytes were treated with GATA4 siRNA1 (5 0 -GGA UUU AUU ACG UAU AUA U-3 0 ), GATA4 siRNA2 (5 0 -UCA GUA UUU AAC UAA UAA A-3 0 ), and murine astrocytes were treated with GATA4 siRNA1 (5 0 -GGA UUU AAU UCG UAU AUA-3 0 ), GATA4 siRNA2 (5 0 -CAC AGA AUA GCU UCA A-3 0 ). siRNAs were generated from Qiagen Inc. (Valencia, CA, USA). Scrambled siRNA controls used were All-star scramble siRNA (Qiagen Inc.). siRNA was delivered to cultured cells using Qiagen Hiperfect transfection reagent (Qiagen Inc.) to a final concentration of 20 nM.
For GATA4 overexpression, human GATA4 cDNA in a pCMV6-XL4 expression vector (NCBI accession number NM_002052) from OriGene (Rockville, MD, USA) (clone SC124037) was delivered using Fugene HD transfection reagent (Roche Inc., Mississauga, Ontario, Canada). Figure 6 Gata4 knockdown increases proliferation and apoptotic resistance in p53 null astrocytes, whereas Gata4 overexpression decreases proliferation and increases activated Caspase levels. (a) Thymidine incorporation assay shows that GATA4 knockdown increases 5-bromodeoxyuridine (BrdU) incorporation in p53 null astrocytes with significance on days 2-5 after Gata4 transfection compared with controls, *Po0.02. Representative western blot showing Gata4 knockdown over a 5-day period. (b) Transient overexpression of Gata4 reduces BrdU incorporation over 5 days, with significance on days 2 and 3 after Gata4 transfection, *Po0.05. Representative western blot showing induction of Gata4 and p15Ink4b. (c) . Western blot for cell cycle markers on day 3 show induction of p15Ink4b and reduced levels of cyclin D1. (d). Gata4 knockdown in p53 À/À astrocytes decreased activated Caspase 3/7 levels when subjected to camptothecin or 5-Gy irradiation. Overexpression of GATA4 increased Caspase 3/7 levels in absence of apoptotic stimuli and these astrocytes still retain higher levels of Caspase 3/7 when subjected to camptothecin or 5-Gy irradiation. Representative western blot showing loss of p53, Gata4 in p53 null astrocytes treated with GATA4 small interfering RNA (siRNA) and increased Gata4 expression in cells treated with Gata4 expression vector. *Po0.05. RLU denotes relative luciferase units.
GATA4, a regulator of astrocyte cell proliferation and apoptosis S Agnihotri et al pCMV6-XL4 with no cDNA insert was used as an empty vector control. For GATA4 overexpression in murine astrocytes, murine GATA4 (NCBI accession number NM_008092) in a pMT2 expression vector was used (a gift from Dr David Wilson, Washington University, St Louis) with empty pMT2 used as a negative control.
Stable knockdowns
Short hairpin sequences based on murine GATA4 siRNA1 and siRNA2 were cloned into pSIREN retroQ (Clonetech Laboratories, Mountain View, CA, USA). p53-null astrocytes were transfected with this construct and GATA4 stable shRNA clones were screened for puromycin resistance (2 mg/ GATA4, a regulator of astrocyte cell proliferation and apoptosis S Agnihotri et al ml) and verified by western blot for GATA4 knockdown. Sequences are available on request.
Western blot analysis
Astrocytes cultured in vitro were lysed with standard PLC lysis buffer. In all, 30 mg of protein lysates were loaded into 10 or 12% SDS-polyacrylamide gel electrophoresis gels. Proteins were then transferred onto PVDF membrane and probed for varying proteins: GATA4 (G4; Santa Cruz Inc., 1:200), b-actin (Sigma-Aldrich Inc., Oakville, Ontario, Canada, 1:5000), p15INK4B (K-18, Santa Cruz Inc., 1:200), cyclin D1 (Santa Cruz Inc., 1:400), cyclin D2 (Abcam, Cambridge, MA, USA, 1:400), p16INK4A (Santa Cruz Inc., 1:250), p19Arf (Santa GATA4, a regulator of astrocyte cell proliferation and apoptosis S Agnihotri et al Cruz Inc., 1:200) and p53 (Vector Shield, Burlingame, CA, USA, 1:300). Protein detection was carried out by using Chemiluminescence Reagent Plus (PerkinElmer Inc., Waltham, MA, USA).
Flow cytometry
Flow cytometry was done as previously (Kamnasaran et al., 2007) described and detail in Supplementary Materials and Methods.
Real-time PCR analysis Total RNA isolation was carried out using an RNA extraction kit total (RNeasy extraction kit from Qiagen). cDNA was synthesized from 100 ng of total RNA using the Quantitect RT kit, which includes DNAse treatment (Qiagen). Quantitative real-time PCR was carried out on 40 ng of cDNA template in a final volume of 25 ml using the Chromo4 Real Time PCR detector (MJ Research (Waltham, MA, USA), a division of Bio-Rad Laboratories Ltd) using SYBR green fluorescence. Primer sequences and real-time PCR method can be obtained from Supplementary Materials and Methods.
In vitro proliferation assay Proliferation was measured using the Cell Proliferation ELISA, BrdU (chemiluminescent) assay (Roche Pharmaceuticals). Briefly, cells were fixed and stained with anti-5-bromodeoxyuridine-POD antibody. Immune complexes and reactions were quantified using a multi-well luminometer.
Apoptosis assays
Briefly, 5 Â 10 3 cells were seeded into a 96-well plate, transfected with siRNA, and at 48 h after transfection, 10 mm camptothecin (Sigma-Aldrich) or 5-Gy irradiation was administered. Caspase 3/7 activity levels were measured using the Apo-One Homogeneous Caspase 3/7 assay (Promega Corp., Madison, WI, USA). See Supplementary Materials and Methods for PE-Annexin-V staining protocol.
Soft agar assay for in vitro transformation
Soft agar plates were poured with a base layer of 0.5% agar in 6-well culture plates. A total of 10 000 cells were counted and mixed with equal volume of 0.75% soft agar for the top layer.
Four ml of Dulbecco's modified Eagle's medium þ 10% fetal bovine serum media was poured on top of the agar overlay and colonies were counted after 14 days. Soft agar experiments were repeated in triplicate.
ChIP assay
Chromatin immunoprecipitation assays were carried out as previously described (Shang et al., 2002) . GATA4 antibody (G4; Santa Cruz Biotechnology Inc.) and normal murine IgG (Santa Cruz Inc.) were used for immunoprecipitation. Primer sequences used for ChIP analysis are described in Supplementary Materials and Methods.
Statistical analysis
All experiments were carried out in triplicate with means and standard error of the mean subjected to Student's t-test. Significance was defined at Po0.05.
